Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
Tailored Sonidegib Schedule After Complete Response in BCC

drug. The tailored schedule consists of a change in the time of drug assumption. It implements some weeks of assumption and some weeks of suspension of sonidegib rather than a continuous administration

  • 0 views
  • 28 Mar, 2021
  • 1 location
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places

squamous cell carcinoma
platelet count
pembrolizumab
monoclonal antibodies
irinotecan
  • 0 views
  • 27 Feb, 2022
  • 3 locations
A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma (SONIB)

In this study, patients with BCC will be given neoadjuvant treatment with a drug called sonidegib. Sonidegib is a daily tablet usually given for BCC that cannot be removed by surgery or that has

adjuvant therapy
carcinoma
imiquimod
sonidegib
scarring
  • 5 views
  • 02 Jul, 2022
  • 1 location
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and tolerability of CX-4945, preliminary evidence of …

renal function
basal cell nevus syndrome
metastatic basal cell carcinoma
metastasis
neutrophil count
  • 13 views
  • 06 Feb, 2022
  • 5 locations
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Approximately 90% of children with malignant brain tumors that have recurred or relapsed after receiving conventional therapy will die of disease. Despite this terrible and frustrating outcome, continued treatment of this population remains fundamental to improving cure rates. Studying this relapsed population will help unearth clues to why conventional therapy …

ribociclib
filgrastim
trametinib
sonidegib
gemcitabine
  • 224 views
  • 19 Apr, 2022
  • 1 location
Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma (NISSO)

Collect real world safety data on the use of sonidegib in adult patients with laBCC. Document major safety parameters such as on treatment deaths, adverse events (AEs)/ serious adverse events

sonidegib
sonidegib 200 mg
carcinoma
  • 2 views
  • 25 Mar, 2022
  • 45 locations